Evidence map›Paper›PMID 38341410›Full record

ArticleCell death discovery2024

1,4-dihydroxy quininib activates ferroptosis pathways in metastatic uveal melanoma and reveals a novel prognostic biomarker signature.

Valentina Tonelotto, Marcel Costa-Garcia, Eve O'Reilly, Kaelin Francis Smith, Kayleigh Slater, Eugene T Dillon, Marzia Pendino, Catherine Higgins, Paola Sist, Rosa Bosch and 7 more

Open access · goldAbstract read
In one paragraph

Article in Cell death discovery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
6.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 5 institutions in 3 countries.

Valentina TonelottoUCD Conway Institute, University College Dublin, D04 V1W8, Dublin, Ireland.ORCID http://orcid.org/0000-0001-7441-2700
Marcel Costa-GarciaMedical Oncology Department, Catalan Institute of Cancer (ICO), IDIBELL-OncoBell, Barcelona, Spain.
Eve O'ReillyUCD Conway Institute, University College Dublin, D04 V1W8, Dublin, Ireland.
Kaelin Francis SmithUCD Conway Institute, University College Dublin, D04 V1W8, Dublin, Ireland.
Kayleigh SlaterUCD Conway Institute, University College Dublin, D04 V1W8, Dublin, Ireland.
Eugene T DillonMass Spectrometry Resource, Conway Institute of Biomolecular & Biomedical Research, University College Dublin, D04 V1W8, Dublin, Ireland.
Marzia PendinoUCD Conway Institute, University College Dublin, D04 V1W8, Dublin, Ireland.
Catherine HigginsUCD School of Mathematics & Statistics, University College Dublin, D04 V1W8, Dublin, Ireland.ORCID http://orcid.org/0009-0003-8718-9335
Paola SistDepartment of Life Sciences, University of Trieste, 34127, Trieste, Italy.
Rosa BoschXenopat S.L., Business Bioincubator, Bellvitge Health Science Campus, 08907 L'Hospitalet de Llobregat, Barcelona, Spain.
Sabina PassamontiDepartment of Life Sciences, University of Trieste, 34127, Trieste, Italy.
Josep M PiulatsMedical Oncology Department, Catalan Institute of Cancer (ICO), IDIBELL-OncoBell, Barcelona, Spain.
Alberto VillanuevaXenopat S.L., Business Bioincubator, Bellvitge Health Science Campus, 08907 L'Hospitalet de Llobregat, Barcelona, Spain.ORCID http://orcid.org/0000-0001-5164-0006
Federica TramerDepartment of Life Sciences, University of Trieste, 34127, Trieste, Italy.
Luca VanellaDepartment of Drug and Health Sciences, University of Catania, 95125, Catania, Italy.
Michelle CareyMass Spectrometry Resource, Conway Institute of Biomolecular & Biomedical Research, University College Dublin, D04 V1W8, Dublin, Ireland.
Breandán N KennedyUCD Conway Institute, University College Dublin, D04 V1W8, Dublin, Ireland. brendan.kennedy@ucd.ie.ORCID http://orcid.org/0000-0001-7991-4689
University College Dublin · IEUniversity of Trieste · ITBellvitge University Hospital · ESInstitut d'Investigació Biomédica de Bellvitge · ESUniversity of Catania · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Uveal melanoma (UM) is an ocular cancer, with propensity for lethal liver metastases. When metastatic UM (MUM) occurs, as few as 8% of patients survive beyond two years. Efficacious treatments for MUM are urgently needed. 1,4-dihydroxy quininib, a cysteinyl leukotriene receptor 1 (CysLT

Identifiers

PMID38341410
PMCPMC10858877
OpenAlexW4391723402

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.